Fabrazyme (agalsidase beta)
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Fabry Disease
Conditions
Fabry Disease
Trial Timeline
Apr 1, 2006 → —
NCT ID
NCT00312767About Fabrazyme (agalsidase beta)
Fabrazyme (agalsidase beta) is a approved stage product being developed by Sanofi for Fabry Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00312767. Target conditions include Fabry Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00312767 | Approved | Withdrawn |
| NCT00196716 | Phase 2 | Completed |
| NCT00074958 | Phase 2 | Completed |
| NCT00074971 | Phase 3 | Completed |
Competing Products
20 competing products in Fabry Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucerastat | Idorsia | Phase 3 | 72 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Venglustat (GZ402671) + Placebo | Sanofi | Phase 3 | 76 |
| Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| agalsidase beta | Sanofi | Approved | 84 |
| Tropicamide | Sanofi | Pre-clinical | 22 |
| agalsidase beta | Sanofi | Approved | 84 |
| AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine | Sanofi | Approved | 84 |
| Gabapentin + placebo | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| agalsidase beta (GZ419828) + agalsidase alfa | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 3 | 76 |
| Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat | Sanofi | Phase 3 | 76 |
| Iohexol | Sanofi | Phase 1 | 32 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) + Placebo | Sanofi | Approved | 84 |
| Agalsidase beta + Agalsidase beta | Sanofi | Phase 3 | 76 |